Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript
Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript
New automotive OEM design wins and production volume ramps - each major OEM partnership represents $50-150M multi-year revenue potential
Restaurant/QSR chain adoption announcements - enterprise logos validate technology and signal TAM expansion
Quarterly revenue growth acceleration or deceleration versus 80-100% growth expectations
Path to profitability milestones - gross margin expansion and operating expense leverage
high - Revenue heavily dependent on automotive production volumes (cyclical) and restaurant industry capital spending on automation technology. During recessions, automotive OEMs delay new model launches and technology integrations, while QSR chains reduce discretionary technology investments. Consumer spending weakness reduces restaurant traffic and query volumes, directly impacting usage-based revenue. Industrial production and consumer sentiment are leading indicators for customer budget allocation to AI initiatives.
High sensitivity through multiple channels: (1) Valuation multiple compression - as unprofitable growth stock, trades at 20x P/S making it highly sensitive to discount rate changes; (2) Customer financing costs - automotive OEMs and restaurant chains face higher capital costs for technology investments during rising rate environments, extending sales cycles; (3) Company financing - while current debt/equity is minimal at 0.01, future growth may require capital raises that become more expensive in high-rate environments. Rising 10-year yields typically compress high-growth software multiples by 20-40%.
Commoditization of voice AI technology as large language models (LLMs) from OpenAI, Google, and Anthropic integrate multimodal capabilities, potentially eroding differentiation of proprietary Speech-to-Meaning architecture
Automotive industry shift toward centralized computing platforms controlled by OEMs (Tesla model) versus third-party voice AI middleware, reducing addressable market
Privacy regulations (GDPR, CCPA expansion) increasing compliance costs for voice data processing and potentially limiting training data access
growth - Attracts speculative growth investors focused on AI thematic exposure and TAM expansion narratives. 99% revenue growth and 20x P/S valuation indicate momentum-driven positioning rather than value or income orientation. Negative profitability and high cash burn appeal to venture-style public market investors willing to accept 3-5 year payback horizons. Recent 43% six-month decline suggests loss of momentum investor support.
Trend
+18.6% vs SMA 50 · -21.1% vs SMA 200
Momentum
Heavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2023 | $55.5M $51.4M–$57.8M | — | -$0.40 | — | ±7% | Low2 |
FY2024 | $83.8M $83.4M–$84.3M | ▲ +51.1% | -$0.38 | — | ±7% | High5 |
FY2025 | $167.8M $165.9M–$172.4M | ▲ +100.1% | -$0.23 | — | ±19% | High7 |
Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript
No description available.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
SOUN◀ | $9.47 | +0.00% | $4.1B | — | — | — | 1500 |
| $198.48 | -0.56% | $4.8T | 40.2 | +6547.4% | 5560.3% | 1495 | |
| $276.83 | +3.28% | $4.1T | 33.6 | +642.6% | 2691.5% | 1494 | |
| $413.62 | +1.57% | $3.1T | 24.6 | +1493.2% | 3614.6% | 1477 | |
| $416.50 | +0.92% | $2.0T | 80.0 | +2387.4% | 3619.8% | 1504 | |
| $576.45 | +4.84% | $611.5B | 25.3 | +4885.1% | 2284.5% | 1534 | |
| $341.54 | +1.71% | $587.8B | 135.6 | +3433.8% | 1251.5% | 1517 | |
| Sector avg | — | +1.68% | — | 56.5 | +3231.6% | 3170.4% | 1503 |